Plasmid DNA has long been the workhorse of cell and gene therapy — supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time,…
In gene therapy manufacturing, viral vectors have long been the primary method for gene modification. However, recent innovations, combined with the evolving demands of the genetic medicines market, are driving…
Reducing Lentiviral Vector Manufacturing Timelines with dbDNA™ Lentiviral vectors are essential for some of today’s most transformative cell and gene therapies, from CAR-T to modified stem cell treatments. But…
How AI Assisted Bioprocessing Can Transform Biotech Biotechnology is evolving, but some methods haven’t caught up. Slow experiments, costly materials, and outdated assumptions are holding back innovation. As demand…
Why Cell-Free DNA Is Replacing Plasmids in Next-Gen Genetic Medicine In the fast-moving world of genetic medicine, cell-free DNA production has the potential to significantly advance the industry by making…
This white paper explores how Touchlight is redefining DNA payload design for next-generation gene editing and non-viral gene therapy. It introduces innovative circular DNA architectures such as mbDNA, sscDNA, hsscDNA,…
As the global demand for RNA-based therapeutics and vaccines accelerates, traditional plasmid DNA (pDNA) production methods often struggle to meet today’s biopharmaceutical landscape’s scalability and efficiency requirements. Touchlight’s z- dbDNA…
How to Scale DNA Production Effectively to Meet the Needs of Genetic Medicines DNA is the blueprint of life, carrying the molecular instructions that tell every cell how to…
This application note highlights the advantages of dbDNA™, a linear, enzymatically amplified DNA construct, as a cell-free alternative to plasmid DNA (pDNA) for lentiviral vector (LVV) production. Manufactured under GMP…